Lyden, Sean |
| Active, not recruiting | N/A | 220 | Europe, US | PQ Bypass System | PQ Bypass, Inc. | Peripheral Arterial Disease | 12/21 | 11/23 | | |
| Recruiting | N/A | 315 | Europe, US | CGuard Carotid Stent implantation, Carotid stenting | InspireMD | Carotid Artery Stenosis | 07/22 | 10/25 | | |
| Active, not recruiting | N/A | 9 | US, RoW | Esprit BTK Device | Abbott Medical Devices | Critical Limb Ischemia (CLI) | 04/23 | 02/28 | | |
TAMBE, NCT05442489: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of the Thoracoabdominal and Pararenal Aortic Aneurysms |
|
|
| Approved for marketing | N/A | | US | GORE Excluder Thoracoabdominal Branch Endoprosthesis, TAMBE | W.L.Gore & Associates | Thoracoabdominal Aneurysm | | | | |
| Active, not recruiting | N/A | 149 | Europe, US | PerQseal® Closure Device System | Vivasure Medical Limited | Percutaneous Large Hole Vascular Closure | 12/24 | 06/25 | | |
SSB 11-02, NCT02777528: Evaluation of the GORE® TAG® Thoracic Branch Endoprosthesis (TBE Device) in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta (Zone 0/1) |
|
|
| Active, not recruiting | N/A | 150 | Japan, US | GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure | W.L.Gore & Associates | Aortic Aneurysm, Thoracic, Aorta, Lesion | 03/24 | 03/28 | | |
| Recruiting | N/A | 500 | US | Pounce Thrombectomy System, Mechanical thrombectomy | SurModics, Inc. | Peripheral Arterial Disease, Acute Limb Ischemia | 05/25 | 07/25 | | |
| Recruiting | N/A | 229 | US | Neuroguard IEP Direct System | Contego Medical, Inc., Yale Cardiovascular Research Group, CardioMed Device Consultants, LLC, Advance Research Associates, iMedNet, AG Mednet | Carotid Stenosis, Carotid Artery Diseases | 06/25 | 07/25 | | |
| Active, not recruiting | N/A | 111 | Europe, US, RoW | GORE® VIAFORT Vascular Stent | W.L.Gore & Associates | Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease | 01/25 | 01/29 | | |
NCT05489588: The GORE® VIAFORT Vascular Stent Iliofemoral Study |
|
|
| Active, not recruiting | N/A | 165 | US | GORE® VIAFORT Vascular Stent | W.L.Gore & Associates | Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease | 04/25 | 04/29 | | |
TAMBE, NCT03728985: Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms |
|
|
| Active, not recruiting | N/A | 102 | Europe, US | GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, TAMBE | W.L.Gore & Associates | Thoracoabdominal Aortic Aneurysm | 01/23 | 09/26 | | |
| Recruiting | N/A | 5000 | Europe, Canada, US, RoW | Any eligible commercially available Boston Scientific Corporation (BSC) drug-eluting device. | Boston Scientific Corporation | Peripheral Vascular Diseases | 01/28 | 01/28 | | |
| Recruiting | N/A | 450 | US | Alto Abdominal Stent Graft System, FDA Approved EVAR AAA Graft Systems | Endologix | AAA, AAA - Abdominal Aortic Aneurysm | 12/28 | 12/28 | | |
NCT05409118: JAGUAR Trial (Outside United States; OUS): ObJective Analysis to GaUge EVAR Outcomes Through Randomization |
|
|
| Not yet recruiting | N/A | 450 | NA | Alto Abdominal Stent Graft System, FDA Approved EVAR AAA Graft Systems, Medtronic Endurant, Cook Zenith, Gore Excluder | Endologix | AAA, AAA - Abdominal Aortic Aneurysm | 12/30 | 12/30 | | |
Jones, Christopher |
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
|
|
| Recruiting | 3 | 200 | US | Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 04/25 | 12/25 | | |
| Recruiting | 3 | 360 | US | Buprenorphine, Zubsolv | Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, National Institute on Drug Abuse (NIDA), Alameda Health System | Opioid Use Disorder | 04/27 | 12/28 | | |
CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial |
|
|
| Recruiting | 3 | 1031 | Canada, US | Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc. | Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma | 01/28 | 05/35 | | |
|
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
STEEL, NCT03809000: A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery |
|
|
| Active, not recruiting | 2 | 188 | Canada, US | Radiation Therapy, RT, Image-Guided Radiation Therapy (IGRT), Radiotherapy, Enzalutamide, Xtandi®, Bicalutamide, Casodex®, GnRH analog, Gonadotropin-releasing hormone analog, Lupron®, leuprolide acetate, goserelin acetate, Eligard™, Viadur™, Zoladex®, Trelstar® | RTOG Foundation, Inc., Pfizer, Astellas Pharma Inc | Prostate Cancer | 04/23 | 09/29 | | |
NCT04225598: Emergency Department-Initiated Buprenorphine Validation Network Trial |
|
|
| Completed | 2 | 2000 | US | CAM2038, Buprenorphine Sublingual Product | Yale University, National Drug Abuse Treatment Clinical Trials Network, The Emmes Company, LLC, Harvard Medical School (HMS and HSDM), University of Pennsylvania, NYU Langone Health, Icahn School of Medicine at Mount Sinai, Alameda Health System, Weill Medical College of Cornell University, National Institute on Drug Abuse (NIDA) | Opioid-use Disorder | 12/24 | 12/24 | | |
OASIS, NCT06636786: Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With Sublingual Cyclobenzaprine HCl (TNX-102 SL) |
|
|
| Not yet recruiting | 2 | 180 | US | Cyclobenzaprine HCl, TNX-102 SL, Placebo, Sugar pill | University of North Carolina, Chapel Hill, United States Department of Defense, Tonix Pharmaceuticals, Inc., Mclean Hospital, Cooper University Health Care | Acute Stress Reaction, Acute Stress Disorder, Neurocognitive Function, Post-traumatic Stress | 09/25 | 09/25 | | |
| Active, not recruiting | N/A | 120 | US | CGM device with diabetic education, CGM education and a follow up protocol., Blind CGM | Intermountain Health Care, Inc., Abbott | Diabetes Mellitus, Type 2 | 07/24 | 12/24 | | |
| Completed | N/A | 68 | US | High Velocity Nasal Insufflation (HVNI), Vapotherm Precision Flow Plus, Noninvasive Positive Pressure Ventilation (NIPPV), Philips Respironics V60 | Vapotherm, Inc., Erlanger Baroness Hospital, The Cooper Health System, Dignity Health - St. John's Regional Medical Center, George Washington University, Madigan Army Medical Center, Valley Presbyterian Hospital, University of Maryland | Hypercapnic Respiratory Failure, Chronic Obstructive Pulmonary Disease, Dyspnea, Hypercapnic Acidosis | 05/23 | 06/23 | | |
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. |
|
|
| Active, not recruiting | N/A | 525 | US | Investigational LUX-Dx ICM Implant | Boston Scientific Corporation | Heart Failure | 05/26 | 06/26 | | |
Conte, Michael |
NCT04267640: Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers |
|
|
| Recruiting | 2 | 60 | US | AMG0001, HGF plasmid, Collategene, beperminogene perplasmid, Placebo | AnGes USA, Inc. | Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot | 07/22 | 01/23 | | |
EnEPC-CLI, NCT02805023: BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) |
|
|
| Recruiting | 1/2 | 50 | US, RoW | BGC101 (autologous EnEPC preparation), Control medium | BioGenCell Ltd., Laniado Hospital, Rabin Medical Center | Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease | 12/27 | 12/27 | | |
NCT04514861: Monitoring Local Tissue Oxygen Changes Using the Wireless Lumee Oxygen Platform in Correlation to TcPO2 |
|
|
| Recruiting | N/A | 53 | US | Wireless Lumee Oxygen Platform | Profusa, Inc., National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI) | Peripheral Artery Disease | 12/21 | 05/22 | | |
| Recruiting | N/A | 450 | US | MiraQ with Transit-Time Flow Measurement (TTFM) and L15 High Frequency Ultrasound (HFUS) probes | Medistim ASA | Chronic Limb-Threatening Ischemia | 12/27 | 12/27 | | |
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia |
|
|
| Recruiting | N/A | 100 | US | LimFlow Stent Graft System | LimFlow, Inc. | Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | 05/27 | 05/27 | | |
Mahmud, Ehtisham |
NCT02661451: Transcatheter Aortic Valve Replacement to UNload the Left Ventricle in Patients With ADvanced Heart Failure (TAVR UNLOAD) |
|
|
| Active, not recruiting | N/A | 178 | Europe, Canada, US | SAPIEN 3 THV, Optimal Heart Failure Therapy | Cardiovascular Research Foundation, New York, Cardialysis BV, Avania | Aortic Valve Stenosis | 02/23 | 02/25 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
| Active, not recruiting | N/A | 1720 | Europe, Canada, US | Microport Firehawk stent, MicroPort Firehawk rapamycin target eluting stent, 2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent) | Shanghai MicroPort Medical (Group) Co., Ltd. | Coronary Artery Disease | 12/23 | 06/27 | | |
ASPIRE PH, NCT04555161: Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System |
|
|
| Recruiting | N/A | 30 | US | Aria CV Pulmonary Hypertension System, Aria CV PH System | Aria CV, Inc | Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction | 10/25 | 10/26 | | |
NCT03523416: Early Feasibility Study - Edwards APTURE Transcatheter Shunt System |
|
|
| Active, not recruiting | N/A | 71 | US | Transcatheter Atrial Shunt System | Edwards Lifesciences | Heart Failure | 12/23 | 11/28 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
Krishnan, Prakash |
| Active, not recruiting | N/A | 260 | Europe, Canada, US, RoW | JETi Peripheral Thrombectomy System | Abbott Medical Devices | Peripheral Artery Thrombosis, Peripheral Venous Thrombosis | 08/24 | 08/25 | | |
| Recruiting | N/A | 200 | US, RoW | Esprit BTK System | Abbott Medical Devices | Chronic Limb-Threatening Ischemia | 04/27 | 05/29 | | |
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia |
|
|
| Recruiting | N/A | 100 | US | LimFlow Stent Graft System | LimFlow, Inc. | Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | 05/27 | 05/27 | | |
Khuddus, Matheen |
| Enrolling by invitation | N/A | 556 | US | Impella ECP | Abiomed Inc. | High-Risk Percutaneous Coronary Intervention | 12/25 | 12/26 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Recruiting | N/A | 1000 | US | Paradise Ultrasound Renal Denervation Treatment, Paradise Ultrasound RDN | ReCor Medical, Inc. | Hypertension, Cardiovascular Diseases, Vascular Diseases | 09/26 | 07/31 | | |
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function |
|
|
| Recruiting | N/A | 1252 | Europe, Canada, US | Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump | Abiomed Inc. | Left Ventricular Dysfunction, Coronary Artery Disease | 03/26 | 10/27 | | |
Lee, Arthur |
| Recruiting | N/A | 376 | Europe, US, RoW | SELUTION SLR™ DEB 014, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities | 06/27 | 07/29 | | |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
| Recruiting | N/A | 300 | Europe, US, RoW | SELUTION SLR™ 018 DEB, Plain (Uncoated) Balloon Angioplasty (PTA) | MedAlliance, LLC, NAMSA, Cordis Corporation | Peripheral Arterial Disease, Superficial Femoral Artery Stenosis | 08/25 | 12/29 | | |
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia |
|
|
| Recruiting | N/A | 100 | US | LimFlow Stent Graft System | LimFlow, Inc. | Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | 05/27 | 05/27 | | |
Ghannadian, Bahman |
| Completed | N/A | 127 | US | Atherectomy Catheter | Avinger, Inc. | Peripheral Arterial Disease | 06/21 | 12/21 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
NCT03523416: Early Feasibility Study - Edwards APTURE Transcatheter Shunt System |
|
|
| Active, not recruiting | N/A | 71 | US | Transcatheter Atrial Shunt System | Edwards Lifesciences | Heart Failure | 12/23 | 11/28 | | |
Knight, Sandra |
ECLIPSE, NCT03108456: Evaluation of Treatment Strategies for Severe CaLcIfic Coronary Arteries: Orbital Atherectomy vs. Conventional Angioplasty Technique Prior to Implantation of Drug-Eluting StEnts: The Trial |
|
|
| Active, not recruiting | N/A | 2005 | US | Orbital Atherectomy, Balloon | Abbott Medical Devices, Cardiovascular Research Foundation, New York | Coronary Artery Disease, Ischemic Heart Disease, Non ST Segment Elevation Myocardial Infarction | 06/24 | 06/25 | | |
Roberson, Marti |
RheSolve, NCT04677465: Clinical Study of the RheOx Bronchial Rheoplasty System in Treating the Symptoms of Chronic Bronchitis |
|
|
| Active, not recruiting | N/A | 270 | Europe, US | RheOx Bronchial Rheoplasty, Sham Procedure | Gala Therapeutics, Inc. | Chronic Bronchitis | 05/24 | 10/25 | | |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |
| Recruiting | N/A | 1000 | US | Paradise Ultrasound Renal Denervation Treatment, Paradise Ultrasound RDN | ReCor Medical, Inc. | Hypertension, Cardiovascular Diseases, Vascular Diseases | 09/26 | 07/31 | | |
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia |
|
|
| Recruiting | N/A | 100 | US | LimFlow Stent Graft System | LimFlow, Inc. | Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | 05/27 | 05/27 | | |
| Active, not recruiting | N/A | 300 | US | Renal Denervation | ReCor Medical, Inc. | Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases | 12/28 | 12/28 | | |
Caputo, Christopher |
| Active, not recruiting | N/A | 300 | US | Renal Denervation | ReCor Medical, Inc. | Hypertension, Hypertension, Resistant to Conventional Therapy, Vascular Diseases, Cardiovascular Diseases | 12/28 | 12/28 | | |
Tong, Ann |
| Recruiting | N/A | 1247 | Europe, Canada, US | Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System | Edwards Lifesciences | Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation | 01/25 | 04/30 | | |
LUX-Dx TRENDS, NCT04790344: Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific's Investigational ICM System. |
|
|
| Active, not recruiting | N/A | 525 | US | Investigational LUX-Dx ICM Implant | Boston Scientific Corporation | Heart Failure | 05/26 | 06/26 | | |
Watts, Caelan |
Polaris-AD, NCT05531526: Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease |
|
|
| Recruiting | 3 | 1150 | Europe, US, RoW | AR1001, Placebo | AriBio Co., Ltd. | Alzheimer Disease | 12/25 | 12/27 | | |
EnEPC-CLI, NCT02805023: BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI) |
|
|
| Recruiting | 1/2 | 50 | US, RoW | BGC101 (autologous EnEPC preparation), Control medium | BioGenCell Ltd., Laniado Hospital, Rabin Medical Center | Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease | 12/27 | 12/27 | | |
NCT05313165: PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia |
|
|
| Recruiting | N/A | 100 | US | LimFlow Stent Graft System | LimFlow, Inc. | Critical Limb Ischemia, Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease | 05/27 | 05/27 | | |
Heflinger, Megan |
| Recruiting | N/A | 380 | Canada, US | Arm 1: treatment with Neovasc Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry | Neovasc Inc., Shockwave Medical, Inc. | Refractory Angina | 06/25 | 12/28 | | |